https://www.selleckchem.com/pr....oducts/Beta-Sitoster
97, 95% CI 1.29-12.27, p=0.016) and ATV intolerance (OR 1.55, 95% CI 1.09-2.19, p=0.014) in patients (n=87 primarily discharged on high dose ATV. In summary, both novel and recognised genetic associations have been identified with circulating levels of ATV and its major metabolites. Further study is warranted to determine the clinical utility of genotyping rs4149056 in patients on high dose ATV. This article is protected by copyright. All rights reserved.Significant in vitro and in vivo evidence supports the potential use of s
Like
Comment
Share
